ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN 印刷: 0893-9675
ISSN オンライン: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2015012997
pages 35-47

Histone Deacetylases and Mechanisms of Regulation of Gene Expression

Hong Ping Chen
Department of Surgery, Boston University Medical School, Boston University, Roger Williams Medical Center, Providence, RI; Department of Histology and Embryology, Medical College, Nanchang University, Nanchang, China
Yu Tina Zhao
Department of Surgery, Boston University Medical School, Boston University, Roger Williams Medical Center, Providence, RI
Ting C. Zhao
Department of Surgery, Boston University Medical School, Boston University, Roger Williams Medical Center, Providence, RI

要約

In recent years it has become widely recognized that histone modification plays a pivotal role in controlling gene expression and is involved in a wide spectrum of disease regulation. Histone acetylation is a major modification that affects gene transcription and is controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs acetylate lysines of histone proteins, resulting in the relaxation of chromatin structure, and they also facilitate gene activation. Conversely, HDACs remove acetyl groups from hyperacetylated histones and suppress general gene transcription. In addition to histones, numerous nonhistone proteins can be acetylated and deacetylated, and they also are involved in the regulation of a wide range of diseases. To date there are 18 HDACs in mammals classified into 4 classes based on homology to yeast HDACs. Accumulating evidence has revealed that HDACs play crucial roles in a variety of biological processes including inflammation, cell proliferation, apoptosis, and carcinogenesis. In this review we summarize the current state of knowledge of HDACs in carcinogenesis and describe the involvement of HDACs in cancer-associated molecular processes. It is hoped than an understanding of the role of HDACs in cancer will lead to the design of more potent and specific drugs targeting selective HDAC proteins for the treatment of the disease.


Articles with similar content:

Modulation of Immune Responses by Histone Deacetylase Inhibitors
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Heiko Brennenstuhl, Ulrike Naumann, Sonja Schotterl
Drugs That Target Gene Expression: An Overview
Critical Reviews™ in Eukaryotic Gene Expression, Vol.6, 1996, issue 1
Filippo Cavalieri
Multifaceted Modulation of SIRT1 in Cancer and Inflammation
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Yun Lu, Xi Chen, Guangwei Liu, Hui Yang, Yujing Bi, Zhengguo Zhang, Yiwei Chu, Jian Wang, Ruifu Yang, Ruoning Wang, Lixiang Xue
Oncogene-lnitiated Aberrant Signaling Engenders the Metastatic Phenotype: Synergistic Transcription Factor Interactions are Targets for Cancer Therapy
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 3-4
David T. Denhardt
Histone Deacetylases and Cancer-Associated Angiogenesis: Current Understanding of the Biology and Clinical Perspectives
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Vincent Castronovo, Andrei Turtoi, Paul Peixoto, Akeila Bellahcene